Trial Profile
Phase II trial of ACH 3422 in combination with ACH 3102 and sovaprevir in treatment-naive patients with hepatitis C
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2015
Price :
$35
*
At a glance
- Drugs ACH 3422 (Primary) ; Odalasvir (Primary) ; Sovaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 05 Mar 2015 Planned initiation date changed from 1 Mar 2015 to 1 Dec 2015, according to an Achillion Pharmaceuticals media release
- 14 Feb 2014 New trial record